- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07621445
Genetic Risk Score of Type 1 Diabetes Mellitus for Progression to Insulin in Diabetic Patients Lack of Predictive Value: a Multicenter Nested Case-control Study
The goal of this observational study is to evaluate the predictive value of the genetic risk score for type 1 diabetes in the progression to insulin deficiency in diabetic patients. The main question it aims to answer is:
- To investigate the predictive efficacy of the genetic risk score for T1DM in determining whether diabetic patients will progress to insulin deficiency;
- To compare the differences in genetic characteristics between the insulin-deficient cohort and the non-insulin-deficient cohort.
This study is a nested case-control study, in which a case group and a control group are set up for the collection of observational indicators. Case group: Diabetic patients who "progressed to insulin deficiency" and those who "progressed to severe insulin deficiency". Control group: Patients who did not progress to insulin deficiency. The study period is 3 years.
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 장소
-
-
Hunan
-
Changsha, Hunan, 중국, 410011
- 모병
- Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
-
연락하다:
- Yang Xiao, MD/PhD
- 전화번호: 86-0731-85292154
- 이메일: xiaoyang29@csu.edu.cn
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
This study will enroll newly-diagnosed diabetic patients whose clinical subtype is unclear. Participants must be aged between 14 and 50 years, with a diabetes diagnosis within the past year, confirmed by standard American Diabetes Association (ADA) criteria. A key pathophysiological criterion is a peak C-peptide level < 200 pmol/L, suggesting impaired insulin secretion.
Key Exclusion Criteria: Patients will be excluded for conditions that could confound the etiology of diabetes or pose additional risks, including:
Specific diabetes subtypes (e.g., gestational diabetes, monogenic diabetes, pancreatic diseases).
Comorbidities such as malignant tumors or severe organ dysfunction. Acute metabolic derangements (e.g., ketoacidosis). Conditions limiting life expectancy or ability to participate (e.g., expected survival < 3 years, psychiatric disorders).
Current pregnancy or lactation.
설명
Inclusion Criteria:
- Gender is not restricted.
- Age ranges from 14 to 50 years old.
Diagnosis of diabetes within < 1 year:
- If there are diabetes symptoms and meet any of the following criteria:① Plasma glucose at any time ≥ 11.1 mmol/L (200 mg/dL), or② Fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL), or③ Plasma glucose 2 hours after OGTT/post - meal ≥ 11.1 mmol/L (200 mg/dL), or④ HbA1c ≥ 6.5%.
- If there are no diabetes symptoms, another test on a different day is required for diagnosis.
- Newly - diagnosed diabetes patients whose type diagnosis is considered unclear clinically.
Exclusion Criteria:
- Peak C-peptide < 200 pmol/L;
- Gestational diabetes, monogenic diabetes (neonatal diabetes, MODY), exocrine pancreatic diseases (cystic fibrosis), diabetes caused by drugs or chemicals;
- Those who have been under long-term treatment with hormones or immunosuppressants;
- Pregnant or lactating women;
- Those with concurrent malignant tumors or severe heart, liver, and kidney diseases;
- Those with an expected survival time of less than 3 years;
- Those with mental disorders or unable to cooperate with the investigation for other reasons;
- Acute phase of diabetic ketoacidosis;
- Stress conditions such as severe infection, fever, trauma, and major surgery;
- Patients lacking major clinical information;
- Those considered by the researcher as unfit to participate in this study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
Patients with diabetes who 'progress to insulin deficiency and severe insulin deficiency'
Patients with diabetes who 'progress to insulin deficiency' and 'progress to severe insulin deficiency'
|
|
Patients who have not progressed to insulin deficiency
For each case, several controls (1:2) were randomly selected from patients in this cohort who had not progressed to insulin deficiency at the same follow - up time point.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
C-peptide
기간: "baseline"、"third year"
|
The primary endpoint is the occurrence of progression to insulin deficiency.
Subjects who "progress to insulin deficiency" are defined as those whose C-peptide level drops to C-peptide < 250 pmol/L during the follow - up period;
|
"baseline"、"third year"
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Fasting and 2 - hour blood glucose
기간: "baseline"、"third year"
|
"baseline"、"third year"
|
|
|
Glycosylated hemoglobin
기간: "baseline"、"third year"
|
"baseline"、"third year"
|
|
|
Whether insulin treatment is needed
기간: "baseline"、"third year"
|
Collect the medical history and current medication information of the subjects.
|
"baseline"、"third year"
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2025 T1DGRS LYF20250124
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .